Company
Ansa Biotechnologies
The complex sequences you need, now directly synthesized up to 900 bp.
Also known as Ansa Biotechnologies, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Founded
- 2018
- Employees
- more than 70 by 2024Source (opens in a new tab)
- Customers
- biotechnology, synthetic biology, and pharmaceutical sectors
- Legal name
- Ansa Biotechnologies, Inc.
- ansabio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At Ansa, you don’t have to design your project around what DNA vendors can or can’t build. You can design the biology you actually want—and get it synthesized the first time. Our enzymatic DNA synthesis platform removes the constraints of assembly-based methods, enabling direct synthesis of complex sequences up to 900 bp and seamless delivery of constructs up to 50 kb.
Funding snapshot
- Total raised
- $124MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $46.4M2024-06-28
Funding rounds
- Round, 2024
- $46.4M2024-06-28, SEC form D sold, 41 investors
- Round, 2022
- $68M2022-03-18, SEC form D sold, 28 investors
- Round, 2021
- $5M2021-10-08, SEC form D sold, 7 investors
- Round, 2020
- $4.7M2020-06-24, SEC form D sold, 24 investors
Loading relationship preview